Comparative Pharmacology
Head-to-head clinical analysis: MECLIZINE HYDROCHLORIDE versus ZERVIATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MECLIZINE HYDROCHLORIDE versus ZERVIATE.
MECLIZINE HYDROCHLORIDE vs ZERVIATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Meclizine is a histamine H1 receptor antagonist that acts centrally in the vestibular system to suppress nausea and vomiting. It also has anticholinergic and sedative effects.
ZERVIATE (cetirizine ophthalmic solution) contains cetirizine, a selective histamine H1 receptor antagonist. It inhibits histamine-induced vasodilation and increased vascular permeability, leading to reduction of ocular itching associated with allergic conjunctivitis.
25-50 mg orally, 3 to 4 times daily for vertigo; 25-50 mg orally 1 hour before travel, may repeat every 24 hours as needed for motion sickness.
1 drop in each affected eye twice daily (approximately 8 hours apart).
None Documented
None Documented
Terminal elimination half-life: 6 hours (range 5-10 hours). Clinical context: Supports twice-daily dosing; steady-state achieved in approximately 24 hours.
Terminal elimination half-life is approximately 3 hours; clinical context: supports twice-daily topical ocular dosing for allergic conjunctivitis.
Renal (unchanged and metabolites): 50%; fecal: 40%; biliary: 10%
Primarily renal excretion of unchanged drug (approximately 70%) and metabolites; biliary/fecal elimination accounts for less than 20%.
Category A/B
Category C
Antihistamine
Antihistamine